Form 4: Ionis Pharmaceuticals Executive Kyle Jenne Awarded Stock Options

EVP, Chief Global Product Strategy Officer of Ionis Pharmaceuticals, Kyle Jenne, was granted stock options for 18,700 shares on January 2, 2025.

Summary

• On January 2, 2025, Kyle Jenne, EVP, Chief Global Product Strategy Officer of Ionis Pharmaceuticals, received a grant of non-qualified stock options.
• The options allow Jenne to purchase 18,700 shares of Ionis Pharmaceuticals common stock at an exercise price of $34.69 per share.
• The options were granted under the Ionis Pharmaceuticals, Inc. 2020 Equity Incentive Plan.
• The options vest over a period of four years, with 25% vesting on January 2, 2026, and the remaining shares vesting in 36 equal monthly installments thereafter.
• Following the transaction, Jenne directly owns 18,700 derivative securities.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation matter, which is generally neutral to positive as it incentivizes management. The sentiment is moderately positive.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and value creation.

Future Outlook

NA

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to attract, retain, and incentivize key executives. This grant is part of Ionis Pharmaceuticals' overall compensation strategy.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for long-term performance incentives.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the executive's performance leads to company growth.
• The grant incentivizes the executive, which could benefit employees through improved company performance.

Key Dates